2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

Detalles Bibliográficos
Autores principales: Ruperto, N, Quartier, P, Wulffraat, N, Woo, P, Loy, A, Mouy, R, Bader-Meunier, B, Prakken, B, Noseda, E, Rordorf, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334176/
http://dx.doi.org/10.1186/1546-0096-6-S1-S2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334176/
http://dx.doi.org/10.1186/1546-0096-6-S1-S2

Ejemplares similares